Category Archives: Cannabics Pharmaceuticals Inc. CNBX

Cannabics Pharmaceuticals, Inc. (CNBX) Safe, Standardized Dosage Cannabics SR Capsules An Ideal Product For Burgeoning MMJ Sector

January 7, 2015

Cannabics Pharmaceuticals, an emerging domestic drug development company with R&D facilities in Israel, which is focused primarily on cannabinoid-based therapies like their flagship product, Cannabics SR, a long-lasting palliative care formulation targeted chiefly at cancer patients, continues expanding its presence in the booming U.S. medical marijuana (MMJ) market. News last month in mid-December that the company has secured engagement in Colorado with Mountain High Products for the manufacturing and distribution of the Cannabics SR extended-release product, comes at an auspicious time, as MMJ retail sales have ballooned to around $300M for the year in Colorado, doing about $32M a month as of late 2014.

Cannabics SR is an ideal product for states like Minnesota and New York, where the recently passed MMJ laws only allow for a 30-day supply of non-smokeable MMJ. Growing receptivity within the medical community and among patients alike has led to unprecedented demand for MMJ to treat a variety of conditions that can be addressed via the increasingly well understood therapeutic properties of cannabinoids. Moreover, many of the conditions for which MMJ is now being prescribed have historically been treated with comparatively more potentially dangerous or habit-forming pharmaceuticals, like opioid derivatives. Consumers are now turning to MMJ for even everyday aches and pains in some cases, seeing MMJ as a relatively benign alternative to the possibly severe and sometimes fatal gastrointestinal bleeding associated with over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs), especially in chronic pain use cases.

Additionally, an oral capsule formulation of cannabinoids, like Cannabics SR, elegantly sidesteps the stigma and potential risks of smoking or vaporizing that many patients dislike, with the added benefit that both elderly and child patients who cannot smoke, are also able to access the therapeutic benefits that such a product has to offer. With the recent landmark FDA approval of a clinical study of cannabidiol (CBD, a non-psychoactive component extracted from cannabis) in childhood epilepsy and a growing number of such studies into the broad-spectrum pain relief, mood elevating and neurological normalizing functions of cannabinoids, the iron is red-hot for a commercial, proprietary formulation that takes advantage of the increasingly promising pharmacokinetics of THC (the psychoactive component of cannabis) and CBD.

Cannabics SR capsules are perfect for patients who are new to MMJ and represent a safe, standardized dosage (10mg of active cannabinoids) that is easy to administer. Unlike most edibles, the amount of THC and the formulation thereof is controlled with Cannabics SR, making the product attractive to new patients, or patients who want to avoid the potentially deleterious psychotropic side effects of a large, unmeasured dosage as is common among edible forms of MMJ.

Comprised of pure, concentrated extracts of carefully selected cannabis strains, Cannabics SR capsules are also completely free of any artificial additives or chemical substances and can easily be double or tripled dosed to achieve therapeutic windows of 8 to 12 (20mg), or 12 to 18 hours (30mg). While it is never recommended for new patients to start a regimen at dosages over 10mg, observational studies have shown a single dose can provide up to 10 to 12 hours of steady-state therapeutic effect on its own, and the rapid onset (20 to 60 minutes) with sustained beneficial effects that is achievable with this formulation, makes the product perfect for once, or twice-daily dosing. It is not unthinkable that such a product could gradually emerge as the standard alternative or companion to common over-the-counter pain medications, as state regulators continue to roll back antiquated restrictions on marijuana.

With nationwide MMJ revenues for 2014 around $2B on only 23 states and DC having created new laws to legalize it, the increasingly inescapable attraction of associated tax revenues for state legislators, like the $7.6M added to Colorado’s state coffers in October 2014, will no doubt continue to put pressure on the remaining states to reform. The future of the market for cannabinoid-based therapy products like Cannabics SR looks solid, but the company isn’t content to rest solely on the laurels of their superb cannabinoid formulation, they are hard at work applying their combined and extensive experience in molecular biology, cancer research and pharmacology to advancing new advanced drugs and therapies, as well as food supplements based on the considerably vast diversity of strains of the cannabis plant.

Learn more about Cannabics Pharmaceuticals by visiting www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc. (CNBX) Proprietary Medical Marijuana Formulation is Ideally Suited for Broad Applications

December 30, 2014

Our scientific understanding of the efficacy of active cannabinoids from the cannabis plant, like THC, the primary psychoactive component, and CBD, a non-psychoactive component, has been systematically hampered by legislation for decades. As a growing body of medical and now even clinical data on the pharmacology of cannabinoids and the human body’s endocannabinoid system emerges however, in the U.S. alone, laws restricting marijuana, especially medical marijuana (MMJ), have been falling left and right. Minnesota and New York have recently both approved some form of MMJ legislation and MMJ is now legal in 23 states, as well as D.C., opening up a massive market opportunity, with companies like GW Pharmaceuticals (NASDAQ: GWPH) already seeing considerable upside from their growing pipeline of cannabinoid indications, like their Multiple Sclerosis spasticity and neuropathic pain drug Sativex®.

One of the major areas of cannabinoid research today is in treating neurological disorders and their effects, with a recent high-water mark being seen in the FDA approval of a CBD study in childhood epilepsy at the Comprehensive Epilepsy Center of New York University. This clinical trial of CBD in epilepsy would put highly quantified data down to extend the growing acceptance of MMJ, expanding data points like the successful use of the CBD-rich and essentially non-psychoactive Charlotte’s Web strain of cannabis to treat Dravet Syndrome (a form of severe and intractable epilepsy) in the Charlotte Figi case. The dramatic reduction of crippling seizures seen in the case of this one eight-year-old girl, whose story was made famous by chief of neurosurgery at Atlanta’s Grady Memorial Hospital, Dr. Sanjay Gupta, is one of the watershed moments in the MMJ industry and seemed to many in the medical community to validate earlier studies done by Stanford University showing an 84% seizure frequency reduction rate in children treated with a variety of (artisanal) CBD.

The growing understanding of the endocannabinoid system, as well as the crucial effects the CB1 and CB2 receptors play in regulating multiple neurological and physiological processes within the body, has led to growing acceptance in the medical community of MMJ and sparked a firestorm of pharmacological development work in CBD by numerous companies. The palliative care market in cancer alone for instance is huge, with tolerability of even chronic MMJ usage a leading factor among pain relief vectors helping to establish overall acceptance. Established opioid developers like (NASDAQ: CARA) are even getting into the game, developing products like their CR701 compound for neuropathic bodily pain as an alternative to comparably dangerous opioids, which may not even work for some patients who have opioid resistant pain.

One of the smaller hot properties in the burgeoning MMJ field today, and one which already has a functional orally-administered cannabinoid product, Cannabics Pharmaceuticals (OTCQB: CNBX), is a superb way for investors to get in on the action. CNBX’s flagship indication, Cannabics SR, is ideally suited to states in the U.S. like Minnesota, where only non-smokable MMJ preparations are currently permitted. Cannabics SR is a proprietary preparation of pure cannabinoids in capsule form designed for cancer patients as palliative care, yet its ingredients have immediate and broader applications as well, applications that are becoming increasingly apparent to healthcare professionals throughout the industry. Cannabics SR has been shown in observational studies to provide a solid 10 to 12 hours of steady-state therapeutic effects, making it an ideal indication for a safe and convenient once-daily dosing regimen.

Cannabics Pharmaceuticals has specifically developed Cannabics SR to deliver an effective one-two punch, using a dual delivery of oil-based compounds in order to provide both quick onset of therapeutic effects within the first 20 to 60 minutes, as well as long-lasting relief via a more concentrated cannabinoid portion within the capsule. This proprietary, sustained release formulation is prepared in GMP (Good Manufacturing Practices) certified facilities and the company has received certification from the Israeli Ministry of Health for an advanced R&D laboratory dedicated to cannabinoid science as well, a lab which they intend to utilize in pursing the cannabinoid-based anti-cancer therapy end of the spectrum further. The company has recently engaged with Mountain High Products LLC, Owner of the “WANA edibles” brand, for the commercialization of its products in the booming Colorado MMJ market. The company has also recently secured an IP licensing and collaboration agreement for the production and distribution of Cannabics SR in Spain with established regional entity Kalapa Holding, which has made a name for itself advancing a tailored medical cannabis therapy approach to the market, emphasizing direct connections between patients and doctors. Cannabics Pharmaceuticals is at the forefront of commercializing clinically tested cannabis-based products and is currently on-track to launch a series of clinical studies in leading medical centers across Israel, where the company’s R&D division is strategically located

With the domestic MMJ market estimated at around $2B annually by IBISWorld, on a CAGR of around 16.2%, CNBX’s move to tackle not just the U.S. market, but the EU and elsewhere, should make investor’s ears perk up. GlobalData pegs the neuropathic pain market alone at around just under $3B, with a projected CAGR of 3.19% through 2022, when they estimate the market will have grown to approximately $3.5B. Needless to say, there is a massive, target-rich environment for CNBX’s advanced cannabinoid medicines both at home and abroad, and as their pipeline develops further amid prevailing legislative acceptance of MMJ, shareholders stand poised to reap the rewards, while also helping patients in dire need.

To learn more about Cannabics Pharmaceuticals, visit: www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc. (CNBX) Inks Letter of Engagement with Mountain High Products

December 19, 2014

Cannabics Pharmaceuticals announced today that it has finalized a letter of engagement with Mountain High Products, a Colorado based, leading cannabis infused products manufacturer and distributor. Mountain High Products offers a diverse line of edible and concentrate products that deliver quality, consistency, and potency.

Under the letter’s terms, Cannabics Pharmaceuticals will license to Mountain High Products the exclusive right to use its proprietary Cannabics SR technology for manufacture and commercialization of the products in the Colorado market. The letter’s terms allow for discussion of additional markets for both parties to enter together upon agreement, as well. Cannabics Pharmaceuticals and Mountain High Products intend to enter into a definitive IP license agreement within the months after operations launch and the start of initial collaboration.

In its production of Cannabics SR medical cannabis products, Mountain High Products will maintain strict compliance with Colorado laws and regulations related to “cannabis infused edible products.” Additionally, these products will be distributed via Mountain High’s distribution channels to certified dispensaries.

Dr. Zohar Koren, CEO of Cannabics Pharmaceuticals, stated, “We are very excited to launch the collaboration with Mountain High Products in Colorado and thus offer our line of advanced medical cannabis products to American patients for the first time. Mountain High Products is an ideal strategic partner for us to launch US commercialization operations and by far the most professional and dedicated manufacturer of edible cannabis products in Colorado.”

Nancy Whiteman, owner of Mountain High Products added, “We are thrilled to partner with Cannabics Pharmaceuticals. From our perspective, the ability to offer an extended release option in cannabis medication will be a game changing improvement to a patient’s medical marijuana experience. The Cannabics SR technology will enable patients to have more consistent and longer lasting relief from pain, insomnia and other medical conditions without the highs and lows of other cannabis options. This is truly a huge step forward for medical marijuana.”

For more information, visit: www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) – Developing Novel Therapies to Answer Medical Needs

December 15, 2014

When used for medicinal purposes, cannabis can have a number of beneficial effects from appetite stimulation to pain relief. Cannabinoids, which can serve as pain relievers, could therefore be used as (or in) medicine for cancer patients. Millions of patients could benefit from the therapeutic effects of these compounds, especially those seeking safe, regulated, easy to administer cannabis-based therapies.

Cannabics Pharmaceuticals is committed to meeting unmet medical needs and designing leading-edge technologies in the field of cannabinoid-based therapies. The company’s research and development efforts are presently focused on the:

• development of administration routes of active cannabinoids

• identification of the interactive, beneficial therapeutic effects of assorted cannabis-based compounds in varied indications

• development of personalized cannabinoid therapies for cancer patients

Through research, Cannabics has collected precious knowledge about the effectiveness of cannabis strains as therapies for specific symptoms. The company continues to develop its genetic and phenotipic database in order to provide better treatments for incapacitating and incurable ailments.

Cannabics’ stated objective is to be one of the first (and few) companies in the world to commercialize cannabis-based medical products that are indication-specific and have been clinically tested. To reach this goal, Cannabics is currently preparing for the launch of a series of rigorously controlled clinical studies in leading medical centers in Israel, where the company’s research and development division is based.

Cannabics Pharmaceuticals is an emerging drug development company that is employing novel technologies in order to develop innovative cannabinoid-based therapies for a range of debilitating ailments. The company is focused on developing and marketing advanced drugs, therapies, food supplements and administration routes based on active ingredients found in strains of the cannabis plant. Cannabics’ flagship product is Cannabics SR, a slow-release medical cannabis capsule designed as a pain-relieving therapy for cancer patients.

For more information, visit the company’s website at www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc.’s (CNBX) Unique Role in the Medical Marijuana Market

December 4, 2014

In its relatively short tenure thus-far, the exploding marijuana market has birthed numerous business opportunities for corporations and pharmaceuticals who see revenue-generating opportunities as a result of loosened medical marijuana laws. One of the sturdiest niches within this industry is edible cannabis-based medicines, driven by a growing number of patients worldwide who benefit from the therapeutic properties of cannabinoids.

The most common oral administration of cannabinoids is through edibles such as cookies, brownies, butter, tea, cakes and lozenges. Countless companies are exploring this market, opening up bakeries and dispensaries offering a wide variety of cannabis edibles.

But because of their “confectionary” packaging, the potency of edibles made from marijuana is unknown and often underestimated. Cannabis-infused edibles usually contain high doses of cannabinoids, which may cause undesirable side effects such as dizziness, anxiety and dissociation. While the oral administration of cannabis has the longest therapeutic window (4-8 hours), the psychoactive side effects are often a deterrent for individuals seeking therapeutic benefit rather than a recreational high.

Cannabics Pharmaceuticals years ago recognized this unmet need for an oral formulation with higher bioavailabity and a lessened peak of psychoactive effect. In fact, the company was founded in 2012 by a team of researchers in the fields of molecular biology, cancer research and pharmacology who embarked upon a mission to formulate a new type of oral capsule with a longer and plateaued therapeutic window and lower psychoactive outcome.

The company’s flagship product is Cannabics SR, an IP-pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Free of any artificial additives or chemical substances, the capsule contains a pure concentrate of cannabinoids derived from select cannabis strains, embedded in a sophisticated and advanced formulation. In observational studies, the Cananbics SR capsules provided beneficial therapeutic effects for 10-12 hours upon a single oral administration. Cannabics SR capsules have been used by certified patients in Israel during the last year, and received highly positive and supportive reviews from both patients and physicians.

Cannabics Pharmaceuticals is now preparing to launch its line of SR products in eligible states of the U.S. and EU markets under existing medical cannabis regulations. As part of its overarching mission, the company recently secured an IP licensing and collaboration agreement with Spain-based Kalapa Holding, which will manufacture and distribute Cannabics SR medical cannabis products to certified patients in the Spanish market.

Through its research and development facility in Israel, Cannabics Pharmaceuticals continues to develop its pipeline of advanced cannabinoid-based therapies, leveraging collaborations with major medical centers in Israel and momentum from its new partnership with Kalapa Holding in Europe.

While the U.S. FDA has yet to approve even basic private research relating to cannabis, much less FDA approval for cannabis-based edible products for medicinal use, the environment is quite different in Israel. Within the Israeli Ministry of Health, there is a stand-alone agency, the Israeli Medical Cannabis Agency, (IMCA), which just last month granted Cannabics Pharmaceuticals a government license to launch their advanced scientific R&D program at their new state of the art laboratory for controlled & exclusive Cannabinoid Research. With this government license and new laboratory, Cannabics Pharmaceuticals is now set to conduct high level scientific and medical research for the identification of novel cannabinoid based therapies, as well as formal and controlled clinical studies in order to gauge and authenticate the true medical benefits of these therapies. An obvious long-term goal for these R&D programs would be the eventual FDA approval and registration as Rx pharmaceuticals of the natural cannabinoid based therapies developed by the company – a goal that has not yet been achieved by any pharmaceutical company in the world.

Unlike most current producers of edible cannabis products, Cannabis Pharmaceuticals is focusing a substantial amount of its energies and funds not only in generating sales, but also in the actual science of cannabinoids, with the goal of developing novel cannabinoid based therapies for various debilitating ailments. Given the penetrating research to date performed by the company, along with their new R&D lab, IMCA license and upcoming clinical studies, it appears that Cannabics Pharmaceuticals may well reach its professed goal of “being a leading pioneer of scientifically proven medical cannabinoid pharmacology”, and much earlier than they had even hoped for.

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) Set to Launch Product Line in Eligible US States and European Markets

November 26, 2014

Through its research and development efforts in Israel, Cannabics Pharmaceuticals is focused on developing a wide and deep pipeline of advanced cannabinoid based therapies. As an integral part to its efforts at building shareholder value, CNBX is committed to working with major medical centers in Israel while exploring the beneficial effects of its products in diverse indications.

The company’s core product is Cannabics SR, which is best defined as a sustained release medical cannabis capsule designed for cancer patients as a palliative care treatment. The company’s proprietary SR technology provides ten to twelve hours of steady-state, beneficial therapeutic effects and, as a result, allows for a convenient oral, once-per-day dosing regimen for patients.

Most notably, CNBX is in preparation to launch its line of SR products in eligible US states and EU markets under existing medical cannabis regulatory policies. The company now finds itself in the final stages of planning a series of formal clinical studies that are anticipated to show the medical benefits of its products aimed at patients suffering from a variety of ailments.

Earlier this month, the company confirmed that it had executed an IP Licensing and Collaboration Agreement with Kalapa Holding, a leading medical cannabis provider and distributor in Spain. Kalapa’s offerings include a wide variety of medical cannabinoid based products. The agreement with Kalapa will provide momentum in the production and distribution of Cannabics SR products within the Spanish market.

In strict compliance with Spanish laws and regulations, Cannabics SR medical cannabis products will be available to certified patients only through a regulated Spanish entity and affiliate of Kalapa Holding, the Asociacion Centro Cannabico de Terapias Naturales. The products will be locally manufactured from pure extracts produced from high quality, organic medical cannabis strains by Kalapa’s affiliate, KSK Labs.

Cannabics Pharmaceuticals is focused on developing and marketing sophisticated drugs, therapies, food supplements and administration routes based on the active ingredients found in unique strains of the cannabis plant.

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) Gains Foothold in Europe

November 20, 2014

Cannabics Pharmaceuticals is an emerging pharmaceutical development company whose flagship product is Cannabics SR, a medical cannabis capsule specifically designed as a palliative care treatment for cancer patients. The company’s proprietary SR technology provides ten to twelve hours of steady-state, beneficial therapeutic effects and, consequently, allows for a convenient oral, once-per-day dosing regimen for patients.

Cannabics has been preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory policies. The company is also now in its final stage of planning a series of formal clinical studies intended to demonstrate the unique medical benefits its products provide to patients suffering from various ailments.

In the first week of November 2014, Cannabics confirmed that it had executed an IP Licensing and Collaboration Agreement with Kalapa Holding, a leading medical cannabis provider and distributor in Spain, whose offerings include a diverse line of medical cannabinoid based products. The Cannabics-Kalapa agreement will guide the production and distribution of Cannabics SR products within the Spanish market.

In strict compliance with Spanish laws and regulations, Cannabics SR medical cannabis products will be available to certified patients only through a regulated Spanish entity and affiliate of Kalapa Holding, the Asociacion Centro Cannabico de Terapias Naturales. The products will be locally manufactured from pure extracts produced from high quality, organic medical cannabis strains by KSK Labs, another Kalapa Holding affiliate.

In collaborating with Kalapa Holding, Cannabics will unite the advanced cannabinoid administration technology implanted in its line of products with Kalapa’s operational capabilities and wide reach within the Spanish medical cannabis market. Management’s hope is that this synergy, which will allow Cannabics to offer its unique advanced products to European patients for the very first time, signals only the beginning of a long-lasting and successful partnership.

Cannabics Pharmaceuticals is focused on developing and marketing sophisticated drugs, therapies, food supplements and administration routes based on the active ingredients found in unique strains of the cannabis plant.

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) Signs Licensing Deal with Spain’s Kalapa Holding

November 6, 2014

Cannabics Pharmaceuticals Inc. announced today that it has signed an IP Licensing and Collaboration Agreement with Kalapa Holding of Spain for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market. Kalapa Holding is a medical cannabis and hemp grower and distributor in Spain, with a wide line of cannabinoid based products.

CANNABICS SR medical cannabis products will be available in strict compliance with Spanish laws and regulations to certified patients through the “Asociacion Centro Cannabico de Terapias Naturales,” a registered Spanish entity and affiliate of Kalapa Holding.

CANNABICS SR products are slated to be produced and distributed locally in Spain, based on pure extracts produced from select, high quality and organic medical cannabis strains cultivated by the Asociacion Centro Cannabico de Terapias Naturales.

“We are very excited to launch the collaboration with Kalapa Holding in Spain and thus offer our line of advanced medical cannabis products to European patients for the first time,” commented Dr. Zohar Koren, CEO of Cannabics Pharmaceuticals. Dr. Zohar continued, “The substantial synergy that arises through the combination of the extensive operational capabilities and outreach of Kalapa Holding in the Spanish medical cannabis market, combined with our advanced cannabinoid administration technology, as embedded in the CANNABICS SR line of products, ensures that this is a long-term and sustainable partnership.”

Cannabics Pharmaceuticals, Inc. is a rising drug development company with endeavors focused on the development, marketing and sales of advanced drugs, food supplements, therapies and administration routes based on the wide range of active ingredients found in strains of the Cannabis plant. CNBX’s flagship product, CANNABICS SR, is an IP pending medical cannabis capsule designed for cancer patients as a palliative care treatment. Cannabics’ proprietary SR technology provides up to 12 hours of beneficial therapeutic relief. The product allows for a convenient oral dosing one or two times per day. Currently, Cannabics is preparing to launch its line of SR products in eligible US states and EU markets under existing medical cannabis regulatory means. At the same time, the company is preparing to introduce a series of formal clinical studies in order to establish the unique medical benefits of its products for patients suffering from various indications.

For more information on the company visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc. (CNBX) Advances on Strength from Israel’s Thriving Medical Marijuana Industry

November 4, 2014

When you hear the words “medical marijuana” your mind is more likely to drift to California than Israel, but the medical marijuana industry in this small Mediterranean country is booming. Unlike in the United States, medical marijuana is legal nationwide in Israel and is estimated to be a $40 million industry with considerable growth.

The Israeli government plays a vital role in the industry’s growth and potential, supporting the research for breakthrough cannabis therapies. Cannabics Pharmaceuticals is taking advantage of this backing and is currently preparing to launch a series of clinical studies in Israel where the company’s research and development division is strategically located. Just last week Cannabics received Government Certification from the Ministry of Health, enabling the company to move forward with its plans to begin advanced laboratory medical research dedicated to cannabinoid science.

Through the course of its own research to date, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for physicians and patients wishing to utilize the unique medical properties of the cannabis plant.

With an aim of being one of the first and few companies to commercialize clinically tested cannabis-based medical products, Cannabics is developing cannabinoid-based anti-cancer therapies starting with its Cannabics SR capsules. The capsules contain a pure concentrate of cannabinoids derived from select cannabis strains. In observational studies, these IP pending medical cannabis capsules provided beneficial therapeutic effects for 10-12 hours upon a single oral administration.

Cannabics will utilize its new laboratory to continue its advanced research program to demonstrate cannabinoids’ potential as a viable source of anti-cancer therapies.

“The exciting scientific field of cannabinoid research has been largely neglected throughout most of the 20th Century due to a total ban on this field of research,” Cannabics CEO Dr. Zohar Koran stated in an earlier news release announcing the certification. “Thus, the available scientific knowledge regarding active cannabinoids and their mechanisms of action in various disease pathways is dramatically lacking in comparison to other therapeutic fields. There is a huge space of uncharted territory to explore with regards to the potential therapeutic roles of this class of compounds for diverse indications.”

Cannabics’ broader plan is to leverage the vast opportunities for research and development in Israel and launch its SR products under existing medical cannabis regulatory pathways in eligible states of the US and EU markets while simultaneously beginning its clinical studies.

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) is Granted Israel Government Certification for Cutting-Edge R&D Lab

October 28, 2014

Cannabics Pharmaceuticals has announced it has received Government Certification from the Ministry of Health in Israel to establish an advanced R&D laboratory dedicated to medical research in the area of cannabinoid science.

Cannabics Pharmaceuticals’ goal is to be one of the first companies in the world to commercialize indication specific and clinically tested cannabis-based medical products. Running in concert with this goal, CNBX is in advanced preparations for the roll out of a series of controlled clinical studies in leading medical centers in Israel where the company’s R&D division is located.

The company’s new state of the art laboratory is designed to use novel technologies to develop innovative cannabinoid based therapies for various disabling ailments.

CEO Dr. Zohar Koren noted, “The exciting scientific field of cannabinoid research has been largely neglected throughout most of the 20th century due to a total ban on this field of research. Thus, the available scientific knowledge regarding active cannabinoids and their mechanisms of action in various disease pathways is dramatically lacking in comparison to other therapeutic fields. There is a huge space of uncharted territory to explore with regards to the potential therapeutic roles of this class of compounds for diverse indications.”

The company is especially interested in the development of cannabinoid-based anti-Cancer therapies.

“The unique properties of active cannabinoids as tumor cell proliferation inhibitors and apoptosis inducers has been known for decades, however this field has never received the appropriate scientific attention it deserves as a potential source for anti-cancer therapies,” commented Dr. Eyal Ballan, Chief Technology Officer. “Our new and expansive laboratory will enable us to perform our advanced research program in this field.”

Cannabics Pharmaceuticals, Inc. is a drug development company whose efforts are focused on the development and commercialization of advanced drugs, food supplements, therapies and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics’ core product is CANNABICS SR — an IP pending medical cannabis capsule used with cancer patients as a palliative care treatment. In observational studies, the company’s proprietary SR technology has shown the ability to provide 10-12 hours of steady state beneficial therapeutic effects profile. This allows for a once-per-day, oral dosing regimen of medical cannabis for patients. CNBX is currently preparing to launch its line of SR products in the US and EU markets under existing medical cannabis regulatory pathways where eligible.

For more information on the company, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc. (CNBX) Offers Innovative Palliative Treatment for Cancer Sufferers

October 16, 2014

The medical marijuana (MMJ) space has been growing by leaps and bounds in recent years as the federal government continues easing their Schedule I enforcement regarding cannabis, allowing states to set the framework on their own so long as it abides by the dictates of federal guidance. This practice has led to 23 states and D.C. adopting some form of MMJ legislation.

One of the leading vectors within the MMJ space has been the extremely positive results that have continued to crop up as a result of testing cannabis therapies against a host of conditions. Of particular note are a variety of chronic/neuropathic pain conditions that can be treated with MMJ, with palliative therapy in cancer patients being one of the most well-known uses and the benefits over typical analgesics like opiates and NSAIDS (non-steroidal anti-inflammatory drugs) continuing to become apparent, especially considering the well-documented appetite simulative effects that are key for conditions like inflammatory bowel disease. Such results have big pharma understandably concerned, as more and more of the pain control market is eaten up each year by MMJ, and the rising star of cannabidiol (CBD) is one of the biggest threats to the pharmaceutical status quo.

CBD is a non-psychoactive compound derived from cannabis which is potentially quite potent depending on the particular strain of cannabis used, even despite the fact that a given strain may be very low in THC (the psychoactive component), as is the case with the now-famous Charlotte’s Web strain used to treat the cripplingly severe seizures of Charlotte Figi, a seven-year-old girl with Dravet Syndrome (a rare and catastrophic form of intractable epilepsy), which caused her to experience multiple seizures per day. The Charlotte’s Web strain has almost no psychoactive effects, yet delivers powerful seizure control capabilities, detailing further the efficacy of MMJ treatment in general for neurological disorders well beyond neuropathic pain.

The anti-cancer prospects are even more tantalizing and with a large body of studies now built up showing broad-spectrum impact in oncology, consumers are getting wise to the potential of THC and CBD rich MMJ treatments. Marijuana Business Daily sees the domestic MMJ space growing to around $8.2B in the next four years, a staggering rise of 200% over the roughly $2.34B estimated by ArcView for this year. With obvious heavy-hitters like GW Pharmaceuticals (NASDAQ: GWPH) already seeing serious upside on their Multiple Sclerosis drug, Sativex®, and a much wider space rapidly emerging that features everything from sodas and edibles, to vaporizer pens and nutraceuticals, the MMJ sector continues to attract new players and investors alike.

One of these players, Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is currently developing a wide range of indication specific medical cannabis therapies for various indications. The company’s flagship product, Cannabics SR, which is designed as a palliative care therapy for oncology patients, has attained GMP (good manufacturing practices) manufacturing capabilities last month, thus placing CNBX’s proprietary product among a select few market-ready offerings to date with this designation for quality. Cannabics SR is based on a sophisticated lipid based formulation that has shown in observational studies the ability provide 10-12 hours of steady state beneficial therapeutic effects for oncology patients upon a single oral administration.

The company continues to advance a broad-spectrum pipeline of offerings and looks to be one of the first to commercialize a range of clinically tested cannabis-based products designed for specific indications. The company is preparing to launch a series of clinical studies at leading medical centers in Israel where their R&D division is strategically located. Over 100 patients have already been treated in Israel with Cannabics SR according to the company’s latest report and they have achieved high levels of satisfaction from both patients and doctors.

More on Cannabics Pharmaceuticals is available at www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals Inc. (CNBX) Putting Bio-technology in a Blooming Traditional Industry

October 6, 2014

It’s common knowledge that law tends to trail technology and social movements, sometimes by years, sometimes by decades. The process of getting new ideas codified in clear and workable legislation can be a long and arduous path, often spotted with periods of contradictory or inconsistently enforced regulations. Nevertheless, after a certain amount of trial and error, the dust eventually settles, issues get clarified, and real changes can take effect.

The mounting pressure to allow the use of cannabinoids for the palliative treatment of patients with cancer and other diseases has begun to open the door to a multi-billion dollar market in the U.S., also potentially generating billions in tax revenue. The amount of money involved in all this has led to contentious ballot measures at state and city levels throughout the country, with increasing degrees of legalization expected to be pushed through for years to come.

Although the legalization of recreational marijuana is in the sites of various activist groups, by far the most wide-spread support continues to focus on cannabinoids for medical use. And it’s not just for cancer. A number of painful and debilitating diseases are now considered targets for the use of medical cannabis. For example, according to a recent report in silive.com (http://dtn.fm/8HtB), both U.S. senators from New York have called on the Department of Justice to allow for the speed up of the state’s new medical marijuana dispensing program for children experiencing epilepsy and other seizure disorders.

However, in spite of the fact that marijuana has already established itself as a major industry in California and elsewhere, it’s an industry that is still largely unorganized and fragmented. As a result, there remain huge quality and information gaps, a mounting problem for new patients who are used to dealing with the medical establishment. The lack of modern controlled research and product development has hampered progress. Still, for some companies, this has represented a unique opportunity.

Cannabics Pharmaceuticals Inc. has been working to introduce much needed technology and control to the development of cannabinoid based products. Interestingly, the company itself does not manufacture, distribute, or dispense any controlled substances. Rather it develops proprietary technologies that are then licensed for use by certified and governmentally approved manufacturers and distributors. Their goal is the scientific determination of efficacy for various cannabis strains as therapies for specific indications, along with the best administration routes for active cannabinoids, something severely lacking in the U.S. medical cannabis industry since regulation essentially halted it nearly a century ago.

The company has already formulated carefully-researched Cannabics SR Capsules targeting cancer patients, and has achieved Good Manufacturing Practices (GMP) capabilities in preparation for its first clinical study of the capsules. Adhering to these practices ranks the company’s products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc. (CNBX) is “One to Watch”

October 1, 2014

Cannabics Pharmaceuticals was founded in 2012 by a group of molecular biology, cancer therapy and pharmacology researchers who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.

Leveraging this expertise and knowledge, Cannabics Pharmaceuticals has created a wide range of solutions for standardized, reproducible and easily administered medical cannabis therapies. The company’s flagship product, Cannabics SR, is a sustained release medical cannabis capsule that contains a pure extract of cannabinoids derived from select cannabis strains, embedded in a sophisticated lipid based formulation. The excipients of the proprietary sustained release formulation are all certified food-grade ingredients, free of artificial additives or chemical substances.

Cannabics SR capsules have been shown to provide beneficial therapeutic effects for 10-12 hours within the therapeutic window. To date, more than 100 patients in Israel – the majority of them oncology patients – have been treated with Cannabics SR capsules as a palliative therapy.

Cannabics Pharmaceuticals intends to launch a series of clinical studies of Cannabics SR capsules in leading medical centers in Israel where the company’s R&D division is strategically located. The results, combined with the superior pharmacokinetic profile of the Cannabics SR formulation, will be the key advantage of Cannabics Pharmaceuticals’ products over competing medical cannabis products available in the market.

Pivoting off of the trial data, the company plans to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. The company has recently achieved Good Manufacturing Practices (GMP) capabilities, thus ranking its products among a very limited number of medical cannabis products available in the US market that are manufactured according to these high-quality standards.

Cannabics Pharmaceuticals’ proprietary technologies are developed in certified laboratories and are licensed to certified manufacturers and distributors with adequate licenses in their local territories. Cannabics Pharmaceuticals itself does not manufacture, distribute, dispense or possess any controlled substances, including cannabis and cannabis-based preparations.

Co-founders Dr. Zohar Koren (CEO) and Dr. Eyal Ballan (CTO) guide the company’s operations with vast experience in medical research and pharmaceutical product development. Under their leadership, Cannabics Pharmaceuticals continues to develop its genetic and phenotipic database to provide superior treatments for incapacitating ailments for which there is no cure, building a pipeline of additional cannabis-based products for indications such as cancer, neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more.

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Cannabics Pharmaceuticals, Inc. (CNBX) Achieves GMP Compliance, Announces Preparation of Clinical Study

September 26, 2014

Cannabics Pharmaceuticals today announced that it has attained Good Manufacturing Practices (GMP) capabilities. Additionally, the company reported it is moving toward the launch of its first clinical study of Cannabics SR capsules.

GMP regulations are designed to ensure that products are produced and controlled according to quality standards. Adhering to these practices ranks Cannabics’ products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.

Cannabics’ Chief Technology Officer Dr. Eyal Ballan stated, “We’re proud to announce GMP standing as we prepare for the upcoming launch of our Cannabics SR capsules. We have developed a product with incredible potential in the oncology market and aim to maintain product integrity throughout the entire manufacturing process.”

Cannabics plans to launch a number of clinical studies in leading medical centers in Israel where the company’s R&D division is strategically located. The company is on track to become one of the first and few companies to commercialize clinically tested cannabis-based products.

“Cannabics SR, our first market ready product, was developed and designed specifically as a palliative therapy for oncology patients,” commented Dr. Ballan. “We are still developing a broad pipeline of additional cannabis based products designed for various indications such as Neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more. Each of these products will be tested in comprehensive and formal clinical studies to prove its efficacy and safety.”

Cannabics emphasized that its products will have a strong advantage over competing medical cannabis products in the market. In addition to the superior pharmacokinetic profile of the Cannabics SR formulations, the company will have clinical results of the efficacy and safety data collected in these formal post-marketing studies.

Cannabics intends to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. Based on a proprietary formulation that contains only certified food ingredients, Cannabics SR capsules will be marketed as a “cannabis-infused edible product” and will be available to certified and registered patients.

In previous observational studies, Cannabics SR capsules has been shown to provide 10-12 hours of reduced nausea and pain while promoting appetite for cancer patients. These capsules are taken only one to two times a day. Also, because they are taken orally as capsules, patients avoid the long-term harmful effects of smoking cannabis.

“Cannabics SR capsules answer a considerable unmet need to alleviate the discomforts of oncology patients without the health hazards associated with smoking cannabis for palliative purpose,” stated Dr. Ballan. “To date, more than 100 patients in Israel (most of them oncology patients) have already been treated with Cannabics SR capsules. The positive responses and high satisfaction level of patients and doctors with this cannabis based therapy option has been overwhelming.”

For more information, visit www.cannabics.com

Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board

Archives

Select A Month
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search

    Categories

    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • AlphaTrade.com APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • Barchart.com (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • BizRocket.com Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (2)
  • BoonMarket.com (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (37)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • Chineseinvestors.com, Inc. CIIX (22)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • Connect-A-Jet.com CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • EFoodSafety.com Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz Inc. EPAZ (22)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Etelcharge.com Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  • Fund.com, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (38)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • GotStocks.net (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenstone Holdings Inc. GSHN (2)
  • GREM USA GRMU (2)
  • Grey Cloak Tech, Inc. GRCK (4)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (17)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (6)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (2)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Loans4Less.com Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (4)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (47)
  • Money4Gold Holdings Inc. MFGD (3)
  • MortgageBrokers.com Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • MyStaru.com Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,352)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (6)
  • OTCPicks.com (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • PetroSun Inc. PSUD (41)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Player's Network, Inc. PNTV (3)
  • Players Network PNTV (4)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (11)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,170)
  • QualityStocks Video Charts (286)
  • QualityStocks.net Market Basics (6)
  • QualityStocksNewsBreaks (11)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (73)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • Smallcaps.us (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,882)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.